Novartis receives FDA nod for ankylosing spondylitis and psoriatic arthritis drug

Novartis receives FDA nod for ankylosing spondylitis and psoriatic arthritis drug

Novartis announced that the US Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) for the treatment of two new indications – adults with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA). AS and PsA are both …

(Visited 1 times, 1 visits today)
3
Like
Save

Comments

Comments are disabled for this post.